Shanghai Henlius Biotech announced that the FDA has granted Orphan Drug Designation for HLX22, an anti-HER2 monoclonal ...

Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximately ...

LUND, SWEDEN / ACCESS Newswire / March 21, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that Dr. Sumeet Ambarkhane MD, Chief Medical Officer, will be leaving Alligator by end o ...

"I wanted to create a bottle that enables you to easily store, transport, and dispense pre/post-workout mixes and pills at the gym or during a workout," said an inventor, from Valrico, Fla., "so I ...

LUND, SE / ACCESS Newswire / March 20, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that the U.S. Food ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

Vici Energy, an integrated energy company, announced today the opening of its new Renovo Energy (Renovo) trading desk in ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal ...

StoneFly, Inc. (iscsi.com) a leader in storage, HCI, backup and disaster recovery, cloud, and AI storage solutions, has announced a significant update to its DR365V appliance, integrating a Secure ...

Against the backdrop of reinforced European and international anti-money-laundering and countering the financing of terrorism (AML/CFT) requirements, the Administration de l’enregistrement, des ...

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard care in this patient population. Perioperative treatment with durvalumab ...